GlassScriptPhysician profile
Marlene J Mash
NPI 1235160334
$6,666.41
in general payments reported to CMS, 2019-2025
27 companies · $396 in 2025
The $396 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,391 · 2020: $809 · 2021: $1,306 · 2022: $659 · 2023: $696 · 2024: $409 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,034 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,034.15 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $466.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $2,803.01 | 2019-2024 | Xeomin |
| Abbvie INC. | $1,156.03 | 2019-2025 | |
| Allergan, INC. | $446.41 | 2019-2022 | |
| Janssen Biotech, INC. | $404.36 | 2019-2021 | |
| Galderma Laboratories, L.P. | $294.73 | 2019-2025 | Dysport |
| Leo Pharma INC. | $212.60 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $200.30 | 2019-2021 | |
| Lilly USA, LLC | $157.71 | 2019-2021 | |
| Pfizer INC. | $155.78 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $129.91 | 2019-2021 | |
| Almirall LLC | $104.10 | 2019-2021 | |
| Revance Therapeutics, INC. | $102.54 | 2025 | Daxxify |
| Paratek Pharmaceuticals, INC. | $93.99 | 2020-2021 | |
| Genzyme Corporation | $82.16 | 2019-2021 | |
| Prugen, INC. Pharmaceuticals | $73.44 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $35.24 | 2019-2020 | |
| Boston Scientific Corporation | $29.81 | 2024 | Wavewriter Alpha Prime 16 |
| Nabriva Therapeutics, Plc | $27.97 | 2020-2021 | |
| Strata Skin Sciences, INC. | $25.37 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $23.91 | 2020 | |
| Journey Medical Corporation | $22.90 | 2019-2020 | |
| Melinta Therapeutics, LLC | $19.73 | 2019 | |
| Glenmark Therapeutics INC. | $15.00 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.47 | 2019 | |
| Merck Sharp & Dohme LLC | $12.88 | 2019 | |
| Dermira, INC. | $11.73 | 2021 | |
| Dusa Pharmaceuticals, INC. | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlene Mash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.